Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

More UK pharmacy news

More news

  • Ventmax SR capsules discontinuedSubscription

    Chiesi has discontinued Ventmax (salbutamol sulphate) SR capsules 4mg and 8mg with immediate effect. Medical information is available on 0161 488 5555.

  • De-noltab discontinuedSubscription

    Astellas is discontinuing De-noltab (tri-potassium di-citrato bismuthate) tablets from 31 December 2015. De-noltab tablets will be available to order until 30 December 2015.

  • Disipal tablets discontinuedSubscription

    Astellas is discontinuing Disipal tablets (orphenadrine hydrochloride) 50mg from 1 December 2015 because of manufacturing issues. Disipal can be ordered until 30 November 2015.

  • Arrhythmia with MoviprepSubscription

    Arrhythmia has been added as an adverse event with unknown frequency to the summary of product characteristics (SPC) for Moviprep (macrogol, sodium sulfate anhydrous, sodium chloride, potassium chloride, ascorbic acid, sodium ascorbate; Norgine). Additionally, the SPC now states that two litres of Moviprep can be taken in the morning of a clinical procedure.

  • Acute coronary syndrome guidelineSubscription

    The Scottish Intercollegiate Guidelines Network (SIGN) has published an updated draft guideline on acute coronary syndrome. The guideline is available for consultation on the SIGN website until 14 August 2015. 

  • Kuvan now indicated for children under four yearsSubscription

    Kuvan (sapropterin dihydrochloride; Merck Serono) is now indicated for use in children with phenylketonuria under four years old who have shown to be responsive. The recommended method of administration in children up to 20kg has also been revised.

  • Extended indication for RelistorSubscription

    Relistor (methylnaltrexone bromide; TMC Pharma Services) is now indicated for opioid-induced constipation when response to laxative therapy has not been sufficient in adults aged 18 years and older. Further changes to the summary of product characteristics reflect this license extension.

  • QT interval prolongation with ZytigaSubscription

    Prolongation of the QT interval has been added as an adverse event with unknown frequency to the summary of product characteristics (SPC) for Zytiga (abiraterone; Janssen-Cilag). The updated SPC now advises caution when administering Zytiga with medicinal products known to prolong the QT interval or those able to induce torsade de pointes.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free newsletters.